Rectal neuroendocrine neoplasms: what the radiologists should know.
Carcinoid
Neoplasm
Neuroendocrine
Rectum
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
12
01
2022
accepted:
21
02
2022
revised:
18
02
2022
pubmed:
16
3
2022
medline:
4
11
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
Neuroendocrine neoplasms of the rectum (R-NENs) are rare; however, their incidence has increased almost threefold in the last few decades. Imaging of R-NENs includes two primary categories: anatomic/morphologic imaging comprised of endoscopic ultrasound (EUS), computed tomography (CT), magnetic resonance imaging (MRI), and functional/molecular imaging comprising of planar scintigraphy, single-photon emission computed tomography (SPECT), and positron emission tomography (PET). The management depends on stage, dimension, atypical features, histological grade, and lymphovascular invasion (LVI). Low-risk local R-NENs can be resected endoscopically, and high-risk or locally advanced neoplasms can be treated with radical surgery and lymphadenectomy and/or chemoradiation. The review article focuses on imaging illustrations and discusses applications of different imaging modalities in diagnosing and managing R-NENs.
Identifiants
pubmed: 35288791
doi: 10.1007/s00261-022-03474-9
pii: 10.1007/s00261-022-03474-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4016-4031Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Öberg, K., et al., Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012. 23 Suppl 7: p. vii124–30.
Sundin, A., et al., ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology, 2009. 90(2): p. 167-83.
pubmed: 19077417
doi: 10.1159/000184855
Das, S. and A. Dasari, Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep, 2021. 23(4): p. 43.
pubmed: 33719003
pmcid: 8118193
doi: 10.1007/s11912-021-01029-7
Wang, X.-Y., et al., Efficacy and safety of hybrid endoscopic submucosal dissection compared with endoscopic submucosal dissection for rectal neuroendocrine tumors and risk factors associated with incomplete endoscopic resection. Annals of Translational Medicine, 2020. 8(6): p. 368.
pubmed: 32355812
pmcid: 7186704
doi: 10.21037/atm.2020.02.25
Osagiede, O., et al., Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections. J Gastrointest Oncol, 2020. 11(5): p. 836-846.
pubmed: 33209480
pmcid: 7657829
doi: 10.21037/jgo-20-193
de Mestier, L., et al., Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab, 2019. 33(5): p. 101293.
Mandair, D. and M.E. Caplin, Colonic and rectal NET's. Best Pract Res Clin Gastroenterol, 2012. 26(6): p. 775-89.
pubmed: 23582918
doi: 10.1016/j.bpg.2013.01.007
Sahani, D.V., et al., Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology, 2013. 266(1): p. 38-61.
pubmed: 23264526
doi: 10.1148/radiol.12112512
van Essen, M., et al., Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol, 2014. 10(2): p. 102-14.
pubmed: 24322649
doi: 10.1038/nrendo.2013.246
Pirasteh, A., P. Lovrec, and L. Bodei, Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord, 2021. 22(3): p. 539-552.
pubmed: 33783695
doi: 10.1007/s11154-021-09631-7
Lawrence, B., et al., The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011. 40(1): p. 1–18, vii.
Leoncini, E., et al., Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine, 2017. 58(2): p. 368-379.
pubmed: 28303513
pmcid: 5671554
doi: 10.1007/s12020-017-1273-x
Cives, M. and J.R. Strosberg, Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin, 2018. 68(6): p. 471-487.
pubmed: 30295930
doi: 10.3322/caac.21493
Dasari, A., et al., Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol, 2017. 3(10): p. 1335-1342.
pubmed: 28448665
pmcid: 5824320
doi: 10.1001/jamaoncol.2017.0589
Hallet, J., et al., Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer, 2015. 121(4): p. 589-97.
pubmed: 25312765
doi: 10.1002/cncr.29099
Palepu, J., et al., Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry. Indian J Gastroenterol, 2017. 36(6): p. 445-451.
pubmed: 29457213
doi: 10.1007/s12664-017-0808-7
Zhang, X., et al., Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocrine Disorders, 2014. 14(1): p. 54.
pubmed: 25001493
pmcid: 4107480
doi: 10.1186/1472-6823-14-54
Cho, M.Y., et al., Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat, 2012. 44(3): p. 157-65.
pubmed: 23091441
pmcid: 3467418
doi: 10.4143/crt.2012.44.3.157
Tsai, H.J., et al., The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One, 2013. 8(4): p. e62487.
Hauso, O., et al., Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer, 2008. 113(10): p. 2655-64.
pubmed: 18853416
doi: 10.1002/cncr.23883
Genus, T.S.E., et al., Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015. Br J Cancer, 2019. 121(11): p. 966-972.
pubmed: 31649320
pmcid: 6889414
doi: 10.1038/s41416-019-0606-3
Nikou, G.C., et al., Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC endocrine disorders, 2016. 16: p. 8-8.
pubmed: 26872616
pmcid: 4752769
doi: 10.1186/s12902-016-0089-7
Santos, A.P., et al., Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. Int J Endocrinol, 2019. 2019: p. 4518742.
pubmed: 31467527
Sobin LHGM, W.C., UICC TNM classification of malignant tumours. 7th ed. 2009.
Sorbye, H., et al., Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology, 2019. 108(1): p. 54-62.
pubmed: 30153658
doi: 10.1159/000493318
Cavalcanti, M.S., M. Gönen, and D.S. Klimstra, The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. International journal of endocrine oncology, 2016. 3(3): p. 203-219.
pubmed: 30338051
pmcid: 6190579
doi: 10.2217/ije-2016-0006
Yoon, S.N., et al., Clinicopathological characteristics of rectal carcinoids. Int J Colorectal Dis, 2010. 25(9): p. 1087-92.
pubmed: 20397020
doi: 10.1007/s00384-010-0949-y
McDermott, F.D., et al., Rectal carcinoids: a systematic review. Surgical Endoscopy, 2014. 28(7): p. 2020-2026.
pubmed: 24584484
doi: 10.1007/s00464-014-3430-0
Kasuga, A., et al., Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution. J Gastroenterol Hepatol, 2012. 27(12): p. 1801-7.
pubmed: 22743039
doi: 10.1111/j.1440-1746.2012.07218.x
Kim, B.N., et al., Atypical endoscopic features can be associated with metastasis in rectal carcinoid tumors. Surgical Endoscopy, 2008. 22(9): p. 1992.
pubmed: 18568372
doi: 10.1007/s00464-008-0006-x
de Mestier, L., et al., Updating the management of patients with rectal neuroendocrine tumors. Endoscopy, 2013. 45(12): p. 1039-46.
pubmed: 24163193
doi: 10.1055/s-0033-1344794
Ramage, J.K., et al., ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology, 2016. 103(2): p. 139-43.
pubmed: 26730835
doi: 10.1159/000443166
Landry, C.S., et al., A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery, 2008. 144(3): p. 460-466.
pubmed: 18707046
doi: 10.1016/j.surg.2008.05.005
James D. Brierley (Editor), M.K.G.E., Christian Wittekind (Editor), TNM Classification of Malignant Tumours, 8th Edition. 2017.
McConnell, Y.J., Surgical management of rectal carcinoids: trends and outcomes from the Surveillance, Epidemiology, and End Results database (1988 to 2012). Am J Surg, 2016. 211(5): p. 877-85.
pubmed: 27048945
doi: 10.1016/j.amjsurg.2016.01.008
Fields, A.C., et al., New lymph node staging for rectal neuroendocrine tumors. J Surg Oncol, 2019. 119(1): p. 156-162.
pubmed: 30481376
doi: 10.1002/jso.25307
Wei, G., et al., Analysis of risk factors of lymph node metastasis in rectal neuroendocrine neoplasms using multicenter data. Future Oncol, 2018. 14(18): p. 1817-1823.
pubmed: 30019936
doi: 10.2217/fon-2018-0059
Kim, J.Y., et al., Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis. Am J Surg Pathol, 2015. 39(5): p. 632-43.
pubmed: 25724002
doi: 10.1097/PAS.0000000000000400
Kojima, M., et al., Recommendation of long-term and systemic management according to the risk factors in rectal NETs patients. Scientific Reports, 2019. 9(1): p. 2404.
pubmed: 30787304
pmcid: 6382938
doi: 10.1038/s41598-018-37707-z
Kojima, M., et al., Neuroendocrine Tumors of the Large Intestine: Clinicopathological Features and Predictive Factors of Lymph Node Metastasis. Front Oncol, 2016. 6: p. 173.
pubmed: 27486567
pmcid: 4947973
doi: 10.3389/fonc.2016.00173
Sohn, J.H., et al., Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. Cancer Res Treat, 2015. 47(4): p. 813-22.
pubmed: 25715764
pmcid: 4614207
doi: 10.4143/crt.2014.238
Li, P., et al., Analysis of the factors affecting lymph node metastasis and the prognosis of rectal neuroendocrine tumors. Int J Clin Exp Pathol, 2015. 8(10): p. 13331-8.
pubmed: 26722537
pmcid: 4680482
Moon, C.M., et al., Long-Term Clinical Outcomes of Rectal Neuroendocrine Tumors According to the Pathologic Status After Initial Endoscopic Resection: A KASID Multicenter Study. Am J Gastroenterol, 2016. 111(9): p. 1276-85.
pubmed: 27377520
doi: 10.1038/ajg.2016.267
Concors, S.J., et al., Predictors of Metastases in Rectal Neuroendocrine Tumors: Results of a National Cohort Study. Dis Colon Rectum, 2018. 61(12): p. 1372-1379.
pubmed: 30312223
doi: 10.1097/DCR.0000000000001243
Hyun, J.H., et al., Clinical impact of atypical endoscopic features in rectal neuroendocrine tumors. World journal of gastroenterology, 2015. 21(47): p. 13302-13308.
pubmed: 26715813
pmcid: 4679762
doi: 10.3748/wjg.v21.i47.13302
Park, C.H., et al., Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy, 2011. 43(9): p. 790-5.
pubmed: 21735371
doi: 10.1055/s-0030-1256414
Sekiguchi, M., et al., Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion. Journal of Gastroenterology, 2015. 50(12): p. 1184-1189.
pubmed: 25936647
doi: 10.1007/s00535-015-1079-7
Sugimoto, S., et al., The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors. Surgical Endoscopy, 2016. 30(10): p. 4239-4248.
pubmed: 26718357
doi: 10.1007/s00464-015-4735-3
Kitagawa, Y., et al., Enhanced detection of lymphovascular invasion in small rectal neuroendocrine tumors using D2-40 and Elastica van Gieson immunohistochemical analysis. Cancer Med, 2016. 5(11): p. 3121-3127.
pubmed: 27748061
pmcid: 5119967
doi: 10.1002/cam4.935
Kwaan, M.R., J.E. Goldberg, and R. Bleday, Rectal Carcinoid Tumors: Review of Results After Endoscopic and Surgical Therapy. Archives of Surgery, 2008. 143(5): p. 471-475.
pubmed: 18490556
doi: 10.1001/archsurg.143.5.471
Takatsu, Y., et al., Short- and Long-term Outcomes of Laparoscopic Total Mesenteric Excision for Neuroendocrine Tumors of the Rectum. Diseases of the Colon & Rectum, 2017. 60(3).
Kumar, A.S., et al., Transanal endoscopic microsurgery for rectal carcinoids: the largest reported United States experience. Colorectal Dis, 2012. 14(5): p. 562-6.
pubmed: 21831099
doi: 10.1111/j.1463-1318.2011.02726.x
Chen, W.-J., et al., Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors. World journal of gastroenterology, 2015. 21(30): p. 9142-9149.
pubmed: 26290641
pmcid: 4533046
doi: 10.3748/wjg.v21.i30.9142
Anthony, L.B., et al., The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas, 2010. 39(6): p. 767-74.
pubmed: 20664474
doi: 10.1097/MPA.0b013e3181ec1261
Caplin, M., et al., ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology, 2012. 95(2): p. 88-97.
pubmed: 22261972
doi: 10.1159/000335594
Yoshida, M., et al., Endoscopic assessment of invasion of colorectal tumors with a new high-frequency ultrasound probe. Gastrointestinal Endoscopy, 1995. 41(6): p. 587-592.
pubmed: 7672554
doi: 10.1016/S0016-5107(95)70196-6
Kobayashi, K., et al., Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum, 2005. 48(2): p. 285-91.
pubmed: 15714250
doi: 10.1007/s10350-004-0765-y
Chen, H.T., et al., Diagnostic accuracy of endoscopic ultrasonography for rectal neuroendocrine neoplasms. World J Gastroenterol, 2014. 20(30): p. 10470-7.
pubmed: 25132764
pmcid: 4130855
doi: 10.3748/wjg.v20.i30.10470
Ishii, N., et al., Endoscopic submucosal dissection and preoperative assessment with endoscopic ultrasonography for the treatment of rectal carcinoid tumors. Surgical Endoscopy, 2010. 24(6): p. 1413-1419.
pubmed: 20033710
doi: 10.1007/s00464-009-0791-x
Ruf, J., et al., 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med, 2011. 52(5): p. 697-704.
pubmed: 21498531
doi: 10.2967/jnumed.110.083741
Park, H.J., et al., Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. European Radiology, 2020. 30(9): p. 4772-4782.
pubmed: 32346794
doi: 10.1007/s00330-020-06867-w
Howe, J.R., et al., The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas, 2017. 46(6): p. 715-731.
pubmed: 28609357
pmcid: 5502737
doi: 10.1097/MPA.0000000000000846
Liang, P., et al., Prediction of the World Health Organization Grade of rectal neuroendocrine tumors based on CT histogram analysis. Cancer medicine, 2021. 10(2): p. 595-604.
pubmed: 33263225
doi: 10.1002/cam4.3628
Ushigome, H., et al., Difficulty of predicting lymph node metastasis on CT in patients with rectal neuroendocrine tumors. PloS one, 2019. 14(2): p. e0211675-e0211675.
pubmed: 30742649
pmcid: 6370204
doi: 10.1371/journal.pone.0211675
Power, S.P., et al., Computed tomography and patient risk: Facts, perceptions and uncertainties. World journal of radiology, 2016. 8(12): p. 902-915.
pubmed: 28070242
pmcid: 5183924
doi: 10.4329/wjr.v8.i12.902
Mahesh, M. and R.L. Morin, CT Scans and Cancer Risks—A Practical Middle Path. Journal of the American College of Radiology, 2016. 13(7): p. 828-830.
pubmed: 27245992
doi: 10.1016/j.jacr.2016.04.008
Costello, J.E., et al., CT Radiation Dose: Current Controversies and Dose Reduction Strategies. American Journal of Roentgenology, 2013. 201(6): p. 1283-1290.
pubmed: 24261368
doi: 10.2214/AJR.12.9720
Kubo, T., Vendor free basics of radiation dose reduction techniques for CT. European Journal of Radiology, 2019. 110: p. 14-21.
pubmed: 30599851
doi: 10.1016/j.ejrad.2018.11.002
Zinsser, D., et al., Dose Reduction and Dose Management in Computed Tomography - State of the Art. Rofo, 2018. 190(6): p. 531-541.
pubmed: 29534253
doi: 10.1055/s-0044-101261
Farchione, A., et al., Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography. Pancreas, 2016. 45(3): p. 345-54.
pubmed: 26418904
doi: 10.1097/MPA.0000000000000461
Kim, B.C., et al., Lymph node size is not a reliable criterion for predicting nodal metastasis in rectal neuroendocrine tumours. Colorectal Dis, 2016. 18(7): p. O243-51.
pubmed: 27166857
doi: 10.1111/codi.13377
Kudou, M., et al., Essentiality of Imaging Diagnostic Criteria Specific to Rectal Neuroendocrine Tumors for Detecting Metastatic Lymph Nodes. Anticancer Res, 2019. 39(1): p. 505-510.
pubmed: 30591502
doi: 10.21873/anticanres.13141
d'Assignies, G., et al., High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology, 2013. 268(2): p. 390-9.
pubmed: 23533288
doi: 10.1148/radiol.13121628
Kwekkeboom, D.J., et al., Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer, 2010. 17(1): p. R53-73.
pubmed: 19995807
doi: 10.1677/ERC-09-0078
Crona, J. and B. Skogseid, GEP- NETS UPDATE: Genetics of neuroendocrine tumors. Eur J Endocrinol, 2016. 174(6): p. R275-90.
pubmed: 27165966
doi: 10.1530/EJE-15-0972
Treglia, G., et al., Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine, 2012. 42(1): p. 80-87.
pubmed: 22350660
doi: 10.1007/s12020-012-9631-1
Gabriel, M., et al., 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med, 2007. 48(4): p. 508-18.
pubmed: 17401086
doi: 10.2967/jnumed.106.035667
Hennrich, U. and M. Benešová, [(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel, Switzerland), 2020. 13(3): p. 38.
doi: 10.3390/ph13030038
Sadowski, S.M., et al., Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol, 2016. 34(6): p. 588-96.
pubmed: 26712231
doi: 10.1200/JCO.2015.64.0987
Skoura, E., et al., The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J Nucl Med, 2016. 57(1): p. 34-40.
pubmed: 26471695
doi: 10.2967/jnumed.115.166017
Reubi, J.C., et al., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med, 2000. 27(3): p. 273-82.
pubmed: 10774879
doi: 10.1007/s002590050034
Kong, G., et al., Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging, 2019. 46(3): p. 718-727.
pubmed: 30343432
doi: 10.1007/s00259-018-4196-8
Imhof, A., et al., Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol, 2011. 29(17): p. 2416-23.
pubmed: 21555692
doi: 10.1200/JCO.2010.33.7873
Bushnell, D.L., Jr., et al., 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol, 2010. 28(10): p. 1652-9.
pubmed: 20194865
pmcid: 4872330
doi: 10.1200/JCO.2009.22.8585
Bodei, L., et al., Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging, 2012. 39 Suppl 1: p. S93-102.
pubmed: 22388625
doi: 10.1007/s00259-011-2002-y
Severi, S., et al., Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013. 40(6): p. 881-888.
pubmed: 23443937
doi: 10.1007/s00259-013-2369-z
Kwekkeboom, D.J., et al., Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol, 2008. 26(13): p. 2124-30.
pubmed: 18445841
doi: 10.1200/JCO.2007.15.2553
Hope, T.A., et al., Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal Imaging, 2015. 40(6): p. 1432-1440.
pubmed: 25820755
doi: 10.1007/s00261-015-0409-9
Berzaczy, D., et al., Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clinical nuclear medicine, 2017. 42(9): p. 669-674.
pubmed: 28682844
pmcid: 5636054
doi: 10.1097/RLU.0000000000001753
Sawicki, L.M., et al., Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. European Radiology, 2017. 27(10): p. 4091-4099.
pubmed: 28439648
doi: 10.1007/s00330-017-4803-2
Seith, F., et al., Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. La radiologia medica, 2018. 123(11): p. 860-870.
pubmed: 29961229
doi: 10.1007/s11547-018-0917-0
Ohno, Y., et al., Efficacy of Ultrashort Echo Time Pulmonary MRI for Lung Nodule Detection and Lung-RADS Classification. Radiology, 2021: p. 211254.
Delle Fave, G., et al., ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 2016. 103(2): p. 119-24.
pubmed: 26784901
doi: 10.1159/000443168
Shimizu, T., et al., Growth Characteristics of Rectal Carcinoid Tumors. Oncology, 2000. 59(3): p. 229-237.
pubmed: 11053991
doi: 10.1159/000012166
Onozato, Y., et al., Endoscopic treatment of rectal carcinoid tumors. Dis Colon Rectum, 2010. 53(2): p. 169-76.
pubmed: 20087092
doi: 10.1007/DCR.0b013e3181b9db7b
Park, H.-W., et al., Endoscopic submucosal dissection for treatment of rectal carcinoid tumors. Gastrointestinal Endoscopy, 2010. 72(1): p. 143-149.
pubmed: 20381798
doi: 10.1016/j.gie.2010.01.040
Chen, R., et al., Comparison of Endoscopic Mucosal Resection With Circumferential Incision and Endoscopic Submucosal Dissection for Rectal Carcinoid Tumor. Surg Laparosc Endosc Percutan Tech, 2016. 26(3): p. e56-61.
pubmed: 27213787
doi: 10.1097/SLE.0000000000000266
Lee, H.J., et al., A comparison of endoscopic treatments in rectal carcinoid tumors. Surgical Endoscopy, 2016. 30(8): p. 3491-3498.
pubmed: 26514133
doi: 10.1007/s00464-015-4637-4
Bang, B.W., et al., Endoscopic Resection for Small Rectal Neuroendocrine Tumors: Comparison of Endoscopic Submucosal Resection with Band Ligation and Endoscopic Submucosal Dissection. Gastroenterol Res Pract, 2016. 2016: p. 6198927.
pubmed: 27525004
pmcid: 4976186
doi: 10.1155/2016/6198927
Jeon, S.M., et al., Feasibility of salvage endoscopic mucosal resection by using a cap for remnant rectal carcinoids after primary EMR. Gastrointestinal Endoscopy, 2011. 73(5): p. 1009-1014.
pubmed: 21316666
doi: 10.1016/j.gie.2010.12.029
Bertani, E., et al., Assessing appropriateness for elective colorectal cancer surgery: clinical, oncological, and quality-of-life short-term outcomes employing different treatment approaches. International Journal of Colorectal Disease, 2011. 26(10): p. 1317.
pubmed: 21750927
doi: 10.1007/s00384-011-1270-0
Ferrer-Márquez, M., et al., Transanal endoscopic microsurgery for the treatment of uncommon rectal lesions. Cirugía Española (English Edition), 2017. 95(6): p. 335-341.
doi: 10.1016/j.cireng.2017.07.009
Zhou, J.-L., et al., Resection of multiple rectal carcinoids with transanal endoscopic microsurgery: case report. World Journal of Gastroenterology: WJG, 2015. 21(7): p. 2220.
pubmed: 25717261
pmcid: 4326163
doi: 10.3748/wjg.v21.i7.2220
Takatsu, Y., et al., Short- and Long-term Outcomes of Laparoscopic Total Mesenteric Excision for Neuroendocrine Tumors of the Rectum. Dis Colon Rectum, 2017. 60(3): p. 284-289.
pubmed: 28177990
doi: 10.1097/DCR.0000000000000745
Modrek, A.S., et al., Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiat Oncol, 2015. 10: p. 101.
pubmed: 25902707
pmcid: 4464878
doi: 10.1186/s13014-015-0411-y
Brieau, B., et al., Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues. Medicine, 2015. 94(42): p. e1864-e1864.
pubmed: 26496341
pmcid: 4620767
doi: 10.1097/MD.0000000000001864
Al-Toubah, T., M. Cives, and J. Strosberg, Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. Translational gastroenterology and hepatology, 2020. 5.
Cives, M., et al., The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications. Neuroendocrinology, 2019. 109(2): p. 83-99.
pubmed: 30699437
doi: 10.1159/000497355
Xu, G., et al., Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia. Future Oncol, 2021. 17(9): p. 1069-1081.
pubmed: 33136448
doi: 10.2217/fon-2020-0703
Mafficini, A. and A. Scarpa, Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocrine reviews, 2019. 40(2): p. 506-536.
pubmed: 30657883
pmcid: 6534496
doi: 10.1210/er.2018-00160
Koşaloğlu, Z., et al., Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. Oncoimmunology, 2016. 5(11): p. e1213931.
Roberts, J.A., et al., Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti–PD-1/PD-L1 therapy. Human Pathology, 2017. 70: p. 49-54.
pubmed: 29037958
pmcid: 5745271
doi: 10.1016/j.humpath.2017.10.003